Global Trials Roundtable – Controlling Cost And Mitigating Risk

By Ed Miseta, Chief Editor, Clinical Leader

The current economy, patent expirations of multibillion dollar drugs, and the rising cost of clinical trials (and drug development in general) has many in the pharma industry placing an increased emphasis on controlling costs. Companies must do this while continuing to take more trials to a global market and seeking out more strategic relationships with clinical partners.

To gain a better understanding of the current trends in clinical outsourcing, and what can be done to control the cost of trials, Clinical Leader conducted a roundtable discussion with executives from several CROs. The panel included: Paula Brown Stafford, president of clinical development at Quintiles; Wendel Barr, CEO of SynteractHCR, James D. Esinhart, CEO of Chiltern, Wanda Dobrzanski Nisiewicz, VP of Clinical Operations Latin America & North America at inVentive Health Clinical; Silvia Zieher, VP, Clinical Development, Latin America Operations at INC Research; and Ramita Tandon, SVP and general manager at inVentive Health Clinical.